Markus Enzelberger – Startup Investor Profile

Markus Enzelberger is a Partner at Versant Ventures with a current fund size of $102.2M. His investment range is $100K – $5.0M, focusing on Pharmaceuticals (Seed), Pharmaceuticals (Series A), BioTech (Series A), and BioTech (Seed) sectors. He has co-invested with Alexander Mayweg, Beckie Robertson, Bill Link, Brad Bolzon, and Brian Atwood. Markus Enzelberger’s professional career includes a role as Chief Scientific Officer at MorphoSys and involvement in a Series A funding round for Vector BioPharma. He collaborates with entrepreneurs, industry, and academics to create and operate innovative biotech companies in Basel, Switzerland through Versant Ventures. Ridgeline, a Versant Ventures Discovery Engine, works closely with Markus Enzelberger in company building, with a focus on biotechnology companies discovering and developing novel therapeutics.

Location:

Country: Belgium

Investment Regions: EU

Investment Stages: pre-seed, seed

Website: https://www.versantventures.com/team/markus-enzelberger-phd

AI Reasoning: Search found Markus Enzelberger associated with Versant Ventures and involvement in launching Vector BioPharma with a Series A announced August 2022. The most recent identified investment (Vector BioPharma) dates to August 2022, which is more than 12 months prior to the reference date, so classify as not-active.

Low Activity – Only known angel investments more than 12 months ago.

Active – Known angel investments between the last 12 and 6 months.

Very Active – Known angel investments in the last 6 months.